4D-150

4D-150 is investigational and has no established place in therapy. The sponsor describes its intended role as a single, in-office intravitreal "backbone therapy" that would replace repeated anti-VEGF injections rather than extend dosing intervals. The phase 3 4FRONT trials define the population studied for registration: 4FRONT-1 (North America) enrolls adults aged 50 years or older with treatment-naive macular neovascularization secondary to AMD, and 4FRONT-2 (global) enrolls treatment-naive participants and participants previously treated with no more than 4 anti-VEGF injections who were diagnosed no more than 6 months before screening. Both trials require a demonstrated clinical response to aflibercept, BCVA of 25 to 78 ETDRS letters, and central subfield thickness of 500 microns or less, with aflibercept 2 mg as the comparator; target enrollment is 480 participants per trial. By comparison, the approved sustained-delivery option (the port delivery system) is labeled for patients who previously responded to at least 2 anti-VEGF injections and requires surgical implantation, whereas 4D-150 is given by intravitreal injection, the same route used for current anti-VEGF agents. In the PRISM phase 1/2 trial, the sponsor also enrolled participants with severe, recalcitrant disease and high injection burden, a population in which use could be considered if approved. Current anti-VEGF care is delivered by ophthalmologists, predominantly retina specialists, in the office setting and billed under Medicare Part B; 36,398,293 intravitreal anti-VEGF injections were administered to Medicare beneficiaries from 2014 to 2023. Payer utilization management already applies to this class: after step therapy implementation in Medicare, relative use of aflibercept increased by 32.0% and bevacizumab decreased by 33.2%, and in 9 retina practices 96.2% of 2,225 prior authorization requests were approved but 59.6% of approvals delayed care by more than 24 hours. The sponsor reports that CMS has not established a uniform coverage and reimbursement policy for genetic medicine products.